Clinica Baviera (XMAD:CBAV) Piotroski F-Score: 5 (As of Jun. 25, 2026) — 17% Below Median


XMAD:CBAV Clinica Baviera SA XMAD:CBAV
100 GF Score
Price €56.60
GF Value €41.29
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Clinica Baviera Piotroski F-Score?

Clinica Baviera XMAD:CBAV +0.71% 100 Piotroski F-Score is 5 as of Jun. 25, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 64.45% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Clinica Baviera has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Clinica Baviera's Piotroski F-Score or its related term are showing as below:

XMAD:CBAV' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Clinica Baviera was 8. The lowest was 2. And the median was 6.

Clinica Baviera  (XMAD:CBAV) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Clinica Baviera Piotroski F-Score Related Terms


Clinica Baviera Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Clinica Baviera's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinica Baviera Piotroski F-Score Chart

Clinica Baviera Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 7.00 8.00 4.00 5.00

Clinica Baviera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 5.00 6.00 5.00 5.00

XMAD:CBAV vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Clinica Baviera's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinica Baviera Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Clinica Baviera's Piotroski F-Score falls into.


XMAD:CBAV
100GF Score
Clinica Baviera SA XMAD:CBAV
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 9.45 + 5.976 + 13.766 + 14.7 = €43.9 Mil.
Cash Flow from Operations was 18.288 + 14.17 + 20.112 + 23.527 = €76.1 Mil.
Revenue was 74.52 + 65.302 + 81.744 + 86.974 = €308.5 Mil.
Gross Profit was 74.52 + 65.302 + 81.744 + 86.974 = €308.5 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(230.339 + 222.255 + 228.011 + 247.508 + 263.868) / 5 = €238.3962 Mil.
Total Assets at the begining of this year (Mar25) was €230.3 Mil.
Long-Term Debt & Capital Lease Obligation was €68.1 Mil.
Total Current Assets was €74.3 Mil.
Total Current Liabilities was €59.7 Mil.
Net Income was 11.013 + 4.594 + 12.184 + 12.871 = €40.7 Mil.

Revenue was 65.126 + 57.462 + 73.652 + 80.216 = €276.5 Mil.
Gross Profit was 65.126 + 57.462 + 73.652 + 80.216 = €276.5 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(193.944 + 203.014 + 202.738 + 212.394 + 230.339) / 5 = €208.4858 Mil.
Total Assets at the begining of last year (Mar24) was €193.9 Mil.
Long-Term Debt & Capital Lease Obligation was €61.1 Mil.
Total Current Assets was €63.1 Mil.
Total Current Liabilities was €53.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Clinica Baviera's current Net Income (TTM) was 43.9. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Clinica Baviera's current Cash Flow from Operations (TTM) was 76.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=43.892/230.339
=0.19055392

ROA (Last Year)=Net Income/Total Assets (Mar24)
=40.662/193.944
=0.20965846

Clinica Baviera's return on assets of this year was 0.19055392. Clinica Baviera's return on assets of last year was 0.20965846. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Clinica Baviera's current Net Income (TTM) was 43.9. Clinica Baviera's current Cash Flow from Operations (TTM) was 76.1. ==> 76.1 > 43.9 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=68.147/238.3962
=0.28585607

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=61.125/208.4858
=0.29318544

Clinica Baviera's gearing of this year was 0.28585607. Clinica Baviera's gearing of last year was 0.29318544. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=74.305/59.735
=1.24391061

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=63.125/53.069
=1.18948916

Clinica Baviera's current ratio of this year was 1.24391061. Clinica Baviera's current ratio of last year was 1.18948916. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Clinica Baviera's number of shares in issue this year was 16.025. Clinica Baviera's number of shares in issue last year was 16.006. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=308.54/308.54
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=276.456/276.456
=1

Clinica Baviera's gross margin of this year was 1. Clinica Baviera's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=308.54/230.339
=1.33950395

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=276.456/193.944
=1.4254424

Clinica Baviera's asset turnover of this year was 1.33950395. Clinica Baviera's asset turnover of last year was 1.4254424. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Clinica Baviera has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Clinica Baviera (XMAD:CBAV) has a Piotroski F-Score of 5 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Clinica Baviera and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Clinica Baviera's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Clinica Baviera ranks #75 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 35.5%.
Is Clinica Baviera's Piotroski F-Score too high?
Clinica Baviera's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Clinica Baviera's value of 5 is 0% at this industry median. Based on the distribution chart, Clinica Baviera ranks #75 out of 211 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #75 out of 211 companies for Piotroski F-Score. This puts Clinica Baviera in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Clinica Baviera's value of 5 is 0% at this benchmark. Historically, Clinica Baviera's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Clinica Baviera has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.29, compared to a current price of €56.60 — trading 37.1% above its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Medical Diagnostics & Research industry median of 5.00. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current Piotroski F-Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued. The current stock price of €56.60 is trading 37.1% above its estimated GF Value™ of €41.29. GuruFocus considers Clinica Baviera to be Significantly Overvalued.

Key valuation signals for XMAD:CBAV:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: €41.29 vs. price of €56.60 (37.1% above fair value)
  • GF Score™: 100/100 with 4 warning signs
  • Industry Position: 0% at the Medical Diagnostics & Research median (#75 of 211)

No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clinica Baviera Business Description

Other Exchanges 0GWJ:UKD9Z:Germany
Address Paseo de la Castellana 20, Madrid, ESP, 28046
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score

Get the complete analysis for XMAD:CBAV

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.60
Price
€41.29
GF Value